2021
DOI: 10.3390/ijms22062801
|View full text |Cite
|
Sign up to set email alerts
|

Neuromyelitis Optica Spectrum Disorder Treatment—Current and Future Prospects

Abstract: Neuromyelitis optica (NMO) is an immune-mediated demyelinative disorder of the central nervous system affecting mainly the optical nerves and the spinal cord. The recurrent course of the disease, with exacerbations and incomplete remissions, causes accumulating disability, which has a profound impact upon patients’ quality of life. The discovery of antibodies against aquaporin 4 (AQP4) and their leading role in NMO etiology and the formulation of diagnostic criteria have improved appropriate recognition of the… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
14
0
3

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 18 publications
(17 citation statements)
references
References 91 publications
0
14
0
3
Order By: Relevance
“…However, the difference is that health insurance coverage is wider in foreign countries ( 16 ). At present, there is no existing effective treatment for NMOSD, and prevention of relapse is the principal goal of therapy ( 17 , 18 ). In our study, immunosuppressants and corticosteroids were the two most commonly prescribed drugs ( 19 ), and only a small proportion of patients used monoclonal antibodies.…”
Section: Discussionmentioning
confidence: 99%
“…However, the difference is that health insurance coverage is wider in foreign countries ( 16 ). At present, there is no existing effective treatment for NMOSD, and prevention of relapse is the principal goal of therapy ( 17 , 18 ). In our study, immunosuppressants and corticosteroids were the two most commonly prescribed drugs ( 19 ), and only a small proportion of patients used monoclonal antibodies.…”
Section: Discussionmentioning
confidence: 99%
“…Autoantibody biomarkers are an indispensable clinical tool for this purpose. 1 , 2 , 3 , 4 , 5 , 6 Use of autoantibody biomarkers in human medicine includes screening markers to predict disease onset, 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 diagnostic markers to confirm disease identity, 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 and prognostic markers to characterize disease progression, 25 , 26 , 27 , 28 severity, 29 , 30 , 31 , 32 , 33 , 34 , 35 or response to treatment. 36 , 37 , 38 , 39 Autoantibody biomarkers in veterinary medicine mainly are limited to diagnostic use, and less often are used in monitoring disease progression or response to treatment.…”
Section: Introductionmentioning
confidence: 99%
“…Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory disease of the central nervous system) and is characterized by injury to the optic nerve, spinal cord, brainstem, and/or brain parenchyma, which can cause severe visual dysfunction and ambulatory disability ( 1 , 2 ). The retina is one of the sites of inflammation as a result of blood-retinal barrier disruption in NMOSD.…”
Section: Introductionmentioning
confidence: 99%